Abstract
Due to the presence of the blood-brain barrier, there is limited drug access into the brain. In order to overcome this challenge, various strategies have been developed to enhance penetration of drugs into the brain. Of these, the most frequently used are pharmacological technologies or comparable methods being developed for brain-targeting drug delivery using receptor- or adsorptive- or transporter-mediated transcytosis and the nose-to-brain route. It goes without saying that exploration of Brain-targeting drug delivery systems has created another potential option for the treatment of central nervous system diseases. In addition to above methods, other technologies for brain-targeting drug delivery (e.g. chemical delivery systems, prodrugs, pharmacological disruption of the BBB and inhibition of drug efflux by P-glycoprotein) are also summaried in this review.
Keywords: Blood-brain barrier, brain-targeting drug delivery systems, receptor-mediated transcytosis, adsorptive-mediated transcytosis, transporter-mediated transcytosis, nose-to-brain, chemical delivery systems, prodrugs, P-glycoprotein, Targeting drug delivery, colloidal drug, harmful blood-borne substances, small molecule drugs, endothelium cells
Current Pharmaceutical Biotechnology
Title:Perspectives on Brain-Targeting Drug Delivery Systems
Volume: 13 Issue: 12
Author(s): Liangran Guo, Jinfeng Ren and Xinguo Jiang
Affiliation:
Keywords: Blood-brain barrier, brain-targeting drug delivery systems, receptor-mediated transcytosis, adsorptive-mediated transcytosis, transporter-mediated transcytosis, nose-to-brain, chemical delivery systems, prodrugs, P-glycoprotein, Targeting drug delivery, colloidal drug, harmful blood-borne substances, small molecule drugs, endothelium cells
Abstract: Due to the presence of the blood-brain barrier, there is limited drug access into the brain. In order to overcome this challenge, various strategies have been developed to enhance penetration of drugs into the brain. Of these, the most frequently used are pharmacological technologies or comparable methods being developed for brain-targeting drug delivery using receptor- or adsorptive- or transporter-mediated transcytosis and the nose-to-brain route. It goes without saying that exploration of Brain-targeting drug delivery systems has created another potential option for the treatment of central nervous system diseases. In addition to above methods, other technologies for brain-targeting drug delivery (e.g. chemical delivery systems, prodrugs, pharmacological disruption of the BBB and inhibition of drug efflux by P-glycoprotein) are also summaried in this review.
Export Options
About this article
Cite this article as:
Guo Liangran, Ren Jinfeng and Jiang Xinguo, Perspectives on Brain-Targeting Drug Delivery Systems, Current Pharmaceutical Biotechnology 2012; 13 (12) . https://dx.doi.org/10.2174/138920112803341770
DOI https://dx.doi.org/10.2174/138920112803341770 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Current Pharmacological Treatment of Pulmonary Arterial Hypertension
Current Clinical Pharmacology Heart Failure in South America
Current Cardiology Reviews Possible Role of Vascular Risk Factors in Alzheimer's Disease and Vascular Dementia
Current Pharmaceutical Design Role of Membrane Transporters and Metabolizing Enzymes in Ocular Drug Delivery
Current Drug Metabolism Herbal Natural Products As a Source of Monoamine Oxidase Inhibitors: A Review
Current Topics in Medicinal Chemistry Polyphenols from Red Wine Modulate Immune Responsiveness: Biological and Clinical Significance
Current Pharmaceutical Design Chondroitin Sulfate Glycosaminoglycans for CNS Homeostasis-Implications for Material Design
Current Medicinal Chemistry The Promises and Challenges of the Use of Genomics in the Prescription of Exercise in Hypertension
Current Hypertension Reviews Ischemic Neuronal Damage
Current Pharmaceutical Design Beta Blocker Use After Acute Myocardial Infarction in the Patient with Normal Systolic Function: When is it “Ok” to Discontinue?
Current Cardiology Reviews Update of Targeted Therapy-Induced Hypertension: Basics for Non-Oncology Providers
Current Hypertension Reviews Agents Targeting Ras Signaling Pathway
Current Pharmaceutical Design What is Currently the Best Radiopharmaceutical for the Hybrid PET/CT Detection of Recurrent Medullary Thyroid Carcinoma?
Current Radiopharmaceuticals Microbial Polysaccharides and their Derivatives as Current and Prospective Pharmaceuticals
Current Pharmaceutical Design Action of the Aqueous Extract of Sesamum Radiatum Schum. & Tonn.(Pedaliaceae) on the Cardiovascular System of Mammalians: Hypotensive Effect
Current Bioactive Compounds Augmentation Strategies for Clozapine-Resistant Patients with Schizophrenia
Current Pharmaceutical Design Therapeutic Options for Transfusion Related Acute Lung Injury; the Potential of the G2A Receptor
Current Pharmaceutical Design Snake Venom Prothrombin Activators Similar to Blood Coagulation Factor Xa
Current Drug Targets - Cardiovascular & Hematological Disorders A Review of the Diagnostic Scope of Biomarker Techniques, Genetic Screening and Virtual Scanning
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Microwave Irradiated Solid Phase and Catalyst-free Hantzsch 1,4-dihydropyridine Synthesis: Spectral Characterization, Fluorescence Study, and Molecular Crystal Structure
Current Chinese Chemistry